Comparative efficacy and safety of statin monotherapy and their combination with ezetimibe (Results of the Russian retrospective observational study UNISON)
DOI:
https://doi.org/10.34687/2219-8202.JAD.2022.04.0003Keywords:
hyperlipidemia, statins, ezetimibe, combined hypolipidemic therapy, effectiveness, safetyAbstract
Objective. Comparative evaluation of the effectiveness of ezetimibe in combination with statins or statin monotherapy in both primary and secondary prevention of CVD.
Materials and Methods. The design was a retrospective post-registration observational multicenter study. Data set for analysis included patients receiving hypolipidemic therapy for both primary and secondary prevention of CVD in real clinical practice, who received statins for ≥3 months as monotherapy or in combination with ezetimibe in steady state, with initiation of therapy not earlier than 2 years before inclusion. The primary endpoint was the frequency of reaching the target LDL cholesterol levels at the time of study inclusion (%).
Results. The population for the analysis (FAS) was composed of 1000 patients (100%), 250 people in the statin monotherapy group and 750 people in the ezetimibe + statin therapy group. The groups did not differ in clinical, demographic, and laboratory variables, except for a higher prevalence of arterial hypertension and higher baseline lipid values in the statin monotherapy group. Against the background of therapy, LDL-С values decreased by -1.10 ± 1.04 mmol/L (change of -27,5 ± 28.5% from baseline) in the statin monotherapy group and by -1.55 ± 1.17 mmol/L (change of -38.2 ± 25.6 % from baseline) in the combination therapy group, p<0.001. The target LDL-С level in the monotherapy group was achieved by 22.4% of patients compared with 28.8% in the combination therapy group, p=0.049.
Conclusion. In real clinical practice, statin/esetimibe combination therapy is accompanied by more frequent achievement of target LDL cholesterol levels than statin monotherapy: 28.8% vs. 22.4% (p=0.049) due to a more pronounced reduction in LDL cholesterol levels compared with baseline. The addition of ezetimibe to statin therapy increases the probability of achieving the target levels of LDL-С by 29% (odds ratio 0.7139 (0.4998- 1.0091), p=0.0493).
Downloads
References
Национальное общество по изучению атеросклероза. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза [Electronic resource]. Российские рекомендации VII пересмотр, 2020. URL: http://cardio-eur.asia/media/files/clinical_recommendations/Diagnosis_and_correction_of_lipid_metabolism_disorders_for_the_prevention_and_treatment_of_atherosclerosis.pdf (accessed: 07.02.2021).
Оганов Р. Г., Кухарчук В. В., Арутюнов Г. П. и соавт. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика, 2012;11(4) 1-10
Kausik K. Ray, Bart Molemans, W. Marieke Schoonen EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology, 2020 Aug 28. doi.org/10.1093/eurjpc/zwaa047
Ballantyne CM, et al. Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination with Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the Explorer Study. Am J Cardiol. 2007;99:673-680.
Gagne C et al. Efficacy and Safety of Ezetimibe Added to Ongoing Statin Therapy for Treatment of Patients With Hypercholesterolemia Am J Cardiol 2002;90:1084-1091
Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Journal of the American College of Cardiology. 2002;40(12):2125–34. PMID: 12505224
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R et al. Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial. Circulation. 2003;107(19):2409–15. DOI: 10.1161/01.CIR.0000068312.21969.C8
Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F et al. Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). The American Journal of Cardiology. 2007;99(5):673–80. DOI: 10.1016/j.amjcard.2006.10.022
Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE et al. Lipid-altering efficacy of the ezetimibe/ simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Current Medical Research and Opinion. 2006;22(10):2041–53. DOI: 10.1185/030079906X132721
Catapano A, Brady WE, King TR, Palmisano J. Lipid alteringefficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Current Medical Research and Opinion. 2005;21(7):1123–30. DOI: 10.1185/030079905X50642
Cannon CP Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes N Engl J Med 2015;372:2387-97. DOI: 10.1056/NEJMoa1410489
Soon JunHong et al. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clinical Therapeutics 2018 Vol.40 (2) 226-241
Гуревич В.С. Место эзетимиба в оптимальной гиполипидемической терапии: согласованные позиции и дискуссионные вопросы. РМЖ. Медицинское обозрение. 2019;6:11–16.
Гуревич В.С. Комбинированная гиполипидемическая терапия в рекомендациях Европейского общества кардиологов и Европейского общества атеросклероза (ECS/EAS) 2019 г.: место эзетимиба. Consilium Medicum. 2019; 21 (12): DOI: 10.26442/20751753.2019.12.190728
Шапошник И. И., Генкель В. В., Салашенко А. О. Комбинированная гиполипидемическая терапия у пациентов пожилого и старческого возраста. Кардиология. 2020;60(7):1–8
Шапошник И. И., Генкель В. В. Плейотропные эффекты эзетимиба. Кардиология. 2019;59(12S):12–17
Сусеков А. В., Кобалава Ж. Д., Гуревич В. С., Галявич А. С., Каминный А. И., Кашталап В. В., Мареев В. Ю., Шапошник И. И. Возможности клинического применения препарата эзетимиба Отрио (АО «АКРИХИН», Россия) у пациентов высокого и очень высокого сердечно-сосудистого риска, не достигших целевых значений показателей липидного обмена. Заключение Совета экспертов. Кардиология. 2019;59(5S):47–57
Толкачева В.В., Малая И.П., Багманова Н.Х., Кобалава Ж.Д. Изучение биоэквивалентности препаратов эзетимиба у здоровых добровольцев после однократного приема натощак. Consilium Medicum. 2019; 21 (1): DOI: 10.26442/20751753.2019.1.190205
Котовская Ю.В., Ерусланова Е.А. Достижение целевого уровня холестерина липопротеинов низкой плотности: современные возможности. РМЖ. Медицинское обозрение. 2019;3(10(I)):45-48
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 И. В. Сергиенко, M. B. Ежов, В. С. Гуревич, В. К. Зафираки, П. А. Баров, О. В. Цыганкова, Е. А. Цыпленкова, Е. П. Приходько, Н. Г. Виноградова, В. Р. Идиятуллина, Е. В. Вырупаева, М. В. Савченко, Ю. Е. Юхина, А. А. Калиновская, Е. С. Тимощенко, А. А. Некрасов, О. Г. Смоленская, К. С. Манько, Е. В. Тимошина
This work is licensed under a Creative Commons Attribution 4.0 International License.